[go: up one dir, main page]

WO2008015695A3 - Inclusion complex of olopatadine and cyclodextrin - Google Patents

Inclusion complex of olopatadine and cyclodextrin Download PDF

Info

Publication number
WO2008015695A3
WO2008015695A3 PCT/IN2007/000199 IN2007000199W WO2008015695A3 WO 2008015695 A3 WO2008015695 A3 WO 2008015695A3 IN 2007000199 W IN2007000199 W IN 2007000199W WO 2008015695 A3 WO2008015695 A3 WO 2008015695A3
Authority
WO
WIPO (PCT)
Prior art keywords
olopatadine
cylcodextrin
inclusion complex
cyclodextrin
hydroxyalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2007/000199
Other languages
French (fr)
Other versions
WO2008015695A2 (en
Inventor
Subhas Balaram Bhowmick
Ritu Nitin Laddha
Surekha Khopade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2008015695A2 publication Critical patent/WO2008015695A2/en
Publication of WO2008015695A3 publication Critical patent/WO2008015695A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to an inclusion complex of olopatadine or its pharmaceutically acceptable salt and hydroxyalkyl-ß-cylcodextrin, preferably hydroxypropyl-ß-cylcodextrin. The present invention also relates to an aqueous topical solution comprising a therapeutically effective amount of olopatadine or its pharmaceutically acceptable salt; hydroxyalkyl-ß-cylcodextrin, preferably hydroxypropyl-ß-cylcodextrin and hydroxypropyl methylcellulose in an amount sufficient to enhance the physical stability of the solution.
PCT/IN2007/000199 2006-05-15 2007-05-15 Inclusion complex of olopatadine and cyclodextrin Ceased WO2008015695A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN748/MUM/2006 2006-05-15
IN748MU2006 2006-05-15

Publications (2)

Publication Number Publication Date
WO2008015695A2 WO2008015695A2 (en) 2008-02-07
WO2008015695A3 true WO2008015695A3 (en) 2008-05-15

Family

ID=38997575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000199 Ceased WO2008015695A2 (en) 2006-05-15 2007-05-15 Inclusion complex of olopatadine and cyclodextrin

Country Status (1)

Country Link
WO (1) WO2008015695A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544922B (en) * 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration europart ingot ophthalmic composition
TW201336527A (en) * 2012-02-10 2013-09-16 Alcon Res Ltd Aqueous pharmaceutical composition with enhanced stability
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2025137749A1 (en) * 2023-12-27 2025-07-03 Eurofarma Laboratórios S.A. Process for the solubilization of olopatadine and use thereof
CN120241701B (en) * 2025-06-06 2025-08-19 北京爱力佳医药科技有限公司 Olopatadine hydrochloride-containing oral medicine composition and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20050004074A1 (en) * 2003-07-01 2005-01-06 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005004922A1 (en) * 2003-07-04 2005-01-20 Novartis Ag Pharmaceutical compositions comprising peranhydrocyclodextrin
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20050004074A1 (en) * 2003-07-01 2005-01-06 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005004922A1 (en) * 2003-07-04 2005-01-20 Novartis Ag Pharmaceutical compositions comprising peranhydrocyclodextrin
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations

Also Published As

Publication number Publication date
WO2008015695A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2007086001A3 (en) Novel pyridine derivatives
NO2020027I1 (en) glasdegib, optionally in the form of a pharmaceutically acceptable salt, including the maleate salt
MY154909A (en) Novel thiophene derivatives
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
MX2010005889A (en) Novel thiophene derivatives.
WO2007147160A3 (en) Aprepitant compositions
TW200716552A (en) Novel thiophene derivatives
UA93903C2 (en) Tetrahydroisoquinoline derivatives to enhance memory function
WO2007087431A3 (en) Sublingual fentanyl spray
TW200738670A (en) Novel thiophene derivatives
WO2006037981A8 (en) Inhibition of tumour cell migration
WO2005105067A3 (en) Aqueous solutions comprising prednisolone and a cyclodextrin derivative
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
DK2439267T3 (en) Enzyme preparations that give a pure taste
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008026048A3 (en) Stable injectable pharmaceutical compositions of docetaxel
IL193155A0 (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2008015695A3 (en) Inclusion complex of olopatadine and cyclodextrin
WO2008058046A3 (en) Card structures for enhanced stacking strength

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827499

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827499

Country of ref document: EP

Kind code of ref document: A2